Prof Alessandro Doria (Harvard Medical School, Boston, MA, US) discuss Genetics and precision medicine: Personalised prevention of cardiovascular disease in type 2 diabetes:Is it possible?

Questions :

1. Can you tell us about the ACCORD trial and its importance for paving the way for a personalized prevention of CVD?
2. What were your findings to date?
3. How will this data influence further research in the field?
4. What further researches needed to personalize heart health in type 2 diabetes?

Filmed on site at EASD 2019 by Radcliffe Cardiology